Clinical and translational discovery最新文献

{"title":"Inflammatory-associated myeloid dendritic cells reveals associations between chronic lung diseases and lung cancer","authors":"Zhiyu Chen,&nbsp;Jiawei Zou,&nbsp;Fulan Deng,&nbsp;Yaoqing Chu,&nbsp;Lianjiang Tan,&nbsp;Xin Zou,&nbsp;Jie Hao","doi":"10.1002/ctd2.70003","DOIUrl":"https://doi.org/10.1002/ctd2.70003","url":null,"abstract":"<p>The high risk of patients with chronic lung diseases in developing into lung cancer has been recognised, but the key factors driving such procedure are still barely known. Dendritic cells (DCs) as major antigen presenting cells take part in the immune response in the very upstream, and myeloid DCs regulate the inflammation in pulmonary diseases. In this article, we performed single-cell RNA sequencing (scRNA-seq) analyses on DCs from pulmonary diseases. We explore the DC characteristics in chronic lung diseases, lung cancer and healthy control samples. We discover that a special type of DC, which is highly associated with inflammatory, inf-DC, is abundant in lung cancer samples. Furthermore, we find that there are about 10% patients with chronic lung diseases also has such inf-DC-rich pattern. Such proportion is consistent to the fact that about 10% chronic lung disease patients finally developed into cancer. Our findings indicate inf-DC could be a potential factor to predict the risk of chronic lung disease developing into cancer.</p>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142404218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic regulation of Epstein–Barr virus: From bench to bedside","authors":"Xiao Gao,&nbsp;Hao-Xu Yang,&nbsp;Shu Cheng,&nbsp;Hua-Man Cai,&nbsp;Jie Xiong,&nbsp;Wei-Li Zhao","doi":"10.1002/ctd2.357","DOIUrl":"https://doi.org/10.1002/ctd2.357","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Epstein–Barr virus (EBV) is a double-stranded DNA herpesvirus and establishes life-long infection in 95% of the world's populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main body</h3>\u0000 \u0000 <p>EBV is critically involved in multiple diseases. Aberrant signaling pathways, immune escape, and metabolic reprogramming play essential roles in EBV-mediated pathogenesis. However, the underlying mechanisms have not yet been fully elucidated. Here we reviewed recent advances on the epigenetic regulation of EBV pathogenesis, which may translate to potential therapeutic strategies in EBV-associated diseases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Growing evidence has suggested that viral infections reconstruct epigenome to modulate gene expression both in the host and the virus levels.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.357","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142404815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction factors and models for chronic kidney disease in type 2 diabetes mellitus: A review of the literature","authors":"Yan Yang,&nbsp;Bixia Yang,&nbsp;Bin Wang,&nbsp;Hua Zhou,&nbsp;Min Yang,&nbsp;Bicheng Liu","doi":"10.1002/ctd2.355","DOIUrl":"https://doi.org/10.1002/ctd2.355","url":null,"abstract":"<p>Diabetes mellitus (DM) has become a major chronic disease seriously affecting human health. Type 2 diabetes mellitus (T2DM) accounts for about 90% of DM patients, which is the largest type. Approximately 25–35% of T2DM patients develop kidney disease, which not only impacts the survival rate and quality of life but also, to the family and society, are of great economic burden. Early identification of high-risk T2DM patients with kidney disease is crucial for initiating targeted prevention and treatment measures in time to reduce or delay the occurrence and progression of diabetic kidney disease. Previous studies have identified a variety of clinical predictors for the progression of renal function in T2DM patients, including proteinuria, estimated glomerular filtration rate, blood glucose, blood pressure, serum uric acid, dyslipidemia, obesity, smoking, duration of DM, age, gender, race, family history of DM, and diabetic retinopathy. Clinical prediction models based on conventional clinical indicators are instrumental in evaluating the risk of kidney disease in T2DM patients, assisting in patient risk stratification. This article systematically reviews the clinical prediction factors and prediction models associated with the progression of renal function in T2DM patients, providing a comprehensive and current reference for improved clinical assessment of the risk of renal function progression.</p>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.355","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA sequencing data identify a conserved population of metallothionein-expressing macrophages that may be ubiquitous in vital human organs","authors":"Joseph A. Daccache,&nbsp;Francis Eng,&nbsp;Lei Cao,&nbsp;Ning Ma,&nbsp;Stephen C. Ward,&nbsp;Thomas Schiano,&nbsp;Mark Miller,&nbsp;Daniel Herron,&nbsp;Anthony V. Azzara,&nbsp;Steven S. Pullen,&nbsp;Paolo Guarnieri,&nbsp;Costica Aloman,&nbsp;Andrea D. Branch","doi":"10.1002/ctd2.348","DOIUrl":"https://doi.org/10.1002/ctd2.348","url":null,"abstract":"&lt;p&gt;Dear Editor,&lt;/p&gt;&lt;p&gt;We used publicly available single-cell RNA sequencing data to identify conserved tissue macrophage populations in human organs. Among the subsets, we found a rare population of metallothionein-expressing macrophages that are present in all vital organs analyzed. We deeply phenotype this subset and determine their localization in the human liver.&lt;/p&gt;&lt;p&gt;In the first phase, we collected data from 10 livers,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; 21 kidneys&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and 60 lungs,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; and selected myeloid-lineage cells using published annotations and lineage markers: CD68, S100, HLA-II, LYZ, C1Q, and CD74 (Figure S1). After removing dendritic cells, we subclustered monocytes and macrophages (liver, 8,197; kidney, 5,005; lung, 121,536), and identified eight subclusters in the monocyte-macrophage (mono-mac) space, defined by their differentially expressed genes (DEGs) (Figure 1A and Figure S2). We evaluated the relatedness of subclusters across organs by determining the Pearson correlations of fold-changes of 1126 DEGs that were significant [&lt;i&gt;p&lt;/i&gt;.adj &lt; .05 (Bonferroni)] in at least two organs (Figure 1B). Cross-organ correlations confirmed the relatedness of most subsets and were highest for monocytes and cycling macrophages.&lt;/p&gt;&lt;p&gt;A survey of the mono-mac subtypes present in at least two human organs revealed that the abundances of most were similar across organs, but MAC_RES was disproportionately large in the lung (alveolar macrophages) and absent from the kidney (Figure 1C). Subset abundances were compared between fibrotic and control organs and differed significantly for three: monocytes, MAC_RES and &lt;i&gt;SPP1&lt;/i&gt;&lt;sup&gt;+&lt;/sup&gt; macrophages (Figure S2). While most of the eight subsets are widely known, we found an unexpected, small population of macrophages (∼2.5% of each organ) that highly expressed genes coding for metallothioneins (MAC_MT). Metallothioneins are low molecular weight, cysteine-rich proteins that bind metal ions. They enhance angiogenesis, protect against oxidative stress and metal toxicity, and modulate macrophage function.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Gene expression patterns of MAC_MTs were highly correlated across all three organs. Using a Wilcoxon rank-sum test to calculate DEGs, nine genes were significant [FC &gt; 0, &lt;i&gt;p&lt;/i&gt;.adj &lt; .05 (Bonferroni)] in MAC_MTs in all three organs (Figure 1D). Genes encoding metallothioneins were highly expressed by MAC_MTs only, unlike &lt;i&gt;CTSL&lt;/i&gt; and &lt;i&gt;SGK1&lt;/i&gt;, which were expressed by multiple sub-clusters. Of interest, &lt;i&gt;MTF1&lt;/i&gt; and &lt;i&gt;MTF2&lt;/i&gt;, which encode metallothionein transcription factors, were minimally expressed in MAC_MTs but were highly expressed in the CYCLING subset, which may provide a local source of MAC_MTs.&lt;/p&gt;&lt;p&gt;In each organ, two gene signatures were developed, one distinguished MAC_MTs from other non-dendritic myeloid-lineage cells, and the other distinguished MAC_MTs from all other cells in the organ. To generate ","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142099941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and translational mode of single-cell measurements: An artificial intelligent single cell","authors":"Xiangdong Wang,&nbsp;Charles A. Powell,&nbsp;Qin Ma,&nbsp;Jia Fan","doi":"10.1002/ctd2.353","DOIUrl":"https://doi.org/10.1002/ctd2.353","url":null,"abstract":"<p>With rapid development and mature of single-cell measurements, single-cell biology and pathology become an emerging discipline to understand the disease. However, it is important to address concerns raised by clinicians as to how to apply single-cell measurements for clinical practice, translate the signals of single-cell systems biology into determination of clinical phenotype, and predict patient response to therapies. The present Perspective proposes a new system coined as the clinical artificial intelligent single-cell (caiSC) with the dynamic generator of clinical single-cell informatics, artificial intelligent analysers, molecular multimodal reference boxes, clinical inputs and outs, and AI-based computerization. This system provides reliable and rapid information for impacting clinical diagnoses, monitoring, and prediction of the disease at the single-cell level. The caiSC represents an important step and milestone to translate the single-cell measurement into clinical application, assit clinicians’ decision-making, and improve the quality of medical services. There is increasing evidence to support the possibility of the caiSC proposal, since the corresponding biotechnologies associated with caiSCs are rapidly developed. Therefore, we call the special attention and efforts from various scientists and clinicians on the caiSCs and believe that the appearance of the caiSCs can shed light on the future of clinical molecular medicine.</p>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.353","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141966796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on fusion genes in tumours","authors":"Yinyi Chang,&nbsp;Zitong Zhao,&nbsp;Yongmei Song","doi":"10.1002/ctd2.352","DOIUrl":"https://doi.org/10.1002/ctd2.352","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The concept of gene fusion describes the process of fusing two genes into one, which is closely linked to tumour occurrence and development and may even be the direct cause of some tumours. Due to their tumour-specific expression and ability to drive tumour occurrence and development, there is great potential for fusion genes to be used as diagnostic markers and targets for specific types of tumours.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main body</h3>\u0000 \u0000 <p>Although many fusion genes have been detected so far, they mainly focus on a small number of highly recurrent fusion genes detected in patients' tumours. There are few studies on the functional mechanism and clinical relevance of rare gene fusions. Our review discusses the generation mechanisms, detection methods, biological functions, and mechanisms of action of fusion genes. Additionally, we discuss the clinical significance of fusion gene detection in some tumour types.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The function mechanism research of rare gene fusion is very necessary, and more functions of fusion genes independent of unfused/normal genes can be explored in future studies. There is still a long way to go in implementing precision tumour therapy targeting gene fusion.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.352","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141967546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-fat diet effects on brain mitochondrial complex I activity and protein lipoxidation: implications for translational medicine","authors":"Vetriselvan Subramaniyan,&nbsp;Ainil Hawa Jansi,&nbsp;Harshini Muruganantham","doi":"10.1002/ctd2.354","DOIUrl":"https://doi.org/10.1002/ctd2.354","url":null,"abstract":"<p>Recent research has highlighted the significant effects of high-fat diets (HFDs) on brain health, particularly focusing on mitochondrial complex I activity and protein lipoxidation. Mitochondrial complex I, the first enzyme of the electron transport chain, is crucial for oxidative phosphorylation and adenosine triphosphate (ATP) production. In individuals consuming an HFD, complex I activity notably increases, initially appearing beneficial due to enhanced energy production. However, this upregulation is linked to elevated reactive oxygen species (ROS) production, leading to oxidative stress and mitochondrial dysfunction. Over the past 5 years, studies have associated this imbalance with neurodegenerative conditions and cognitive decline in obese individuals.<span>¹</span></p><p>The brain's energy demands are met primarily through oxidative phosphorylation, with mitochondrial complex I playing a pivotal role. In the context of an HFD, complex I activity is upregulated, ostensibly to meet increased energy requirements. However, this heightened activity has a significant downside. Increased complex I activity is closely associated with ROS production, chemically reactive molecules containing oxygen. While ROS are normal byproducts of cellular metabolism, excessive ROS production can overwhelm the cell's antioxidant defences, leading to oxidative stress (Figure 1).<span>^{2, 3}</span></p><p>Oxidative stress is a critical factor in the pathogenesis of neurodegenerative diseases. It damages cellular components, including lipids, proteins and DNA, disrupting normal cellular functions and leading to cell death. In the brain, which has a high metabolic rate and limited regenerative capacity, oxidative stress is particularly detrimental. Studies have shown that in obese individuals, the brain exhibits higher levels of oxidative damage, correlated with cognitive impairments and increased risk of neurodegenerative disorders such as Alzheimer's disease. Lipoxidation, the oxidative modification of proteins by lipid peroxidation products, is another significant consequence of a HFD. Lipid peroxidation is a process where ROS attack polyunsaturated fatty acids in cell membranes, resulting in the formation of reactive lipid aldehydes. These aldehydes can covalently modify proteins, forming advanced lipoxidation end-products (ALEs). ALEs accumulate in neural tissues and alter protein structure and function, leading to impaired cellular processes and neuronal damage.<span>^{4, 5}</span></p><p>The brain's synaptic function is particularly vulnerable to lipoxidation. Synaptic proteins are essential for neurotransmission, and their modification by ALEs can disrupt signal transduction, leading to synaptic dysfunction, cognitive deficits and neurodegenerative changes. Recent studies have provided evidence that the increased ROS production due to elevated complex I activity accelerates lipid peroxidation, thereby enhancing protein lipoxidati","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.354","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141967344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-sectional analysis of pharmaceutical industry payments to board-certified breast cancer specialists in Japan","authors":"Anju Murayama,&nbsp;Kenichi Higuchi,&nbsp;Hinari Kugo","doi":"10.1002/ctd2.331","DOIUrl":"https://doi.org/10.1002/ctd2.331","url":null,"abstract":"<p>Financial interactions between pharmaceutical companies and physicians introduce conflicts of interest among physicians, and can unduly influence physicians' clinical decision-making, such as increased use of non-recommended cancer treatments and higher healthcare expenditures. Breast cancer is the most common cancer for which there is a growing number of novel treatments. Nevertheless, the financial relationships between pharmaceutical companies and physicians treating patients with breast cancer remain unknown. Using payment data disclosed by major pharmaceutical companies in Japan between 2016 and 2020, this study examined size and trends in non-research payments from the pharmaceutical companies to breast cancer specialists who were board-certified by the Japanese Breast Cancer Society. A total of $17.2 million were made to 1349 or 77.8% of all board-certified breast cancer specialists over the five years. Of all specialists, 41.9% to 55.5% received the payments each year. The median payments per specialist were $1,149–$1,371 annually. Only 5op 1% and 10% of all specialists received 24.7% and 70.3% of all payments to the specialists. The payments per specialist significantly increased by 9.9% (95% confidence interval: 6.713.1, <i>p</i> &lt; 0.001) from 2016 to 2019, but decreased by 29.6% (95% CI: −34.4 to −24.5, <i>p</i> &lt; 0.001) in 2020 when the COVID-19 pandemic occurred. Given that even a small payment to physicians is associated with their clinical practice, it is imperative that these breast cancer specialists are more aware of the potential influence of payments on their decision-making.</p>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141966546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke in sickle cell patients, epidemiology, pathophysiology, systemic and surgical treatment options and prevention strategies","authors":"Siddharth Shah,&nbsp;Amelia H. Alberts,&nbsp;Tran B. Ngo,&nbsp;Brandon Lucke-Wold","doi":"10.1002/ctd2.303","DOIUrl":"https://doi.org/10.1002/ctd2.303","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A hereditary haemoglobinopathy known as sickle cell disease (SCD) affects over 100 000 people in the United States severely. Cerebrovascular disease is a prominent consequence of SCD. By the age of 30, 53% of patients have silent cerebral infarcts (SCIs) (a stroke that occurs without any obvious symptoms because it damages a small part of the brain that isn't responsible for any essential functions), and by the age of 40, 3.8% have overt strokes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main body</h3>\u0000 \u0000 <p>The multidimensional burden of cerebrovascular illness in SCD is reviewed in detail in this article, which includes both clinical strokes and the frequently asymptomatic SCIs. The intricate pathophysiology of SCD and stroke is explored. With SCD, there are currently very few methods for preventing primary and secondary stroke; the most common ones are hydroxyurea and blood transfusion. Nevertheless, not enough research has been done on the possible contributions of anticoagulation and aspirin to strokes linked to SCD. Promising evidence is also highlighted in the study, suggesting that new drugs intended to treat SCD may be able to alleviate leg ulcers and renal impairment in addition to reducing unusually high transcranial Doppler flow velocity – a crucial component of cerebrovascular events. Given that these novel medications specifically target haemolysis and vaso-occlusion, the two main causes of strokes in this population, more research is desperately needed to determine whether they are effective in avoiding strokes in people with SCD. The literature review also emphasizes how common healthcare inequities are and how they hinder advancements in SCD research and management in the United States.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>To successfully address these inequities, the evaluation recommends more funding for both SCD management and research, as well as for patient and clinician education. This multimodal viewpoint highlights the intricate terrain of cerebrovascular problems associated with SCD and the urgent need for all-encompassing and fair strategies to improve patient outcomes and advance research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.303","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141968411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The application of aptamers in the field of aging and age-related diseases","authors":"LiuJun Xu,&nbsp;Beier Jiang,&nbsp;WenJing Qiu,&nbsp;Chunxia Jiang,&nbsp;Feng Zhang,&nbsp;Weihong Tan","doi":"10.1002/ctd2.346","DOIUrl":"https://doi.org/10.1002/ctd2.346","url":null,"abstract":"<p>The world is transitioning into an aging society, a phenomenon that escalates the risk of age-related diseases, posing a significant threat to human health. Addressing how to delay aging or achieve healthy aging has become an urgent and pivotal issue. Presently, diverse anti-aging drugs are under development and entering clinical validation stages. However, the absence of specific aging biomarkers has hindered the identification of corresponding targets for diagnosing and treating aging and age-related diseases. Aptamer, a novel molecular recognition tool, has found broad application in diagnosing and treating various diseases. Additionally, cell-based selection holds the potential to identify unidentified molecules that could serve as biomarkers for diseases. Recent years have seen a surge in attention towards aging and age-related diseases, with the application of aptamer in this domain rapidly advancing. Consequently, this review will provide a concise overview of the aging, with a focus on the utilisation of aptamer in aging and age-related diseases.</p>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.346","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141968412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}